NEK9 and pancreatic neoplasm: A similar gemcitabine hypersensitivity was observed following NEK9 knockdown in MIA PaCa-2 human pancreatic cancer cells (Supplementary Figure S2A and B) and HeLa cervical cancer cells (Supplementary Figure S2C), indicating that gemcitabine hypersensitivity following NEK9 knockdown is not cell-type specific.